Breast Cancer
Conditions
Keywords
fibroglandular tissue, tamoxifen, MRI, Background Parenchymal Enhancement, 10-217
Brief summary
Tamoxifen is a hormonal treatment for breast cancer. It prevents recurrent disease and decreases death. Tamoxifen is given to women with and at high risk for breast cancer. These women also commonly have breast MRI to monitor for breast cancer. Some features of normal breast tissue visible on breast MRI change depending on patient hormonal status. It has been questioned if hormonal changes due to tamoxifen are seen on breast MRI. Pilot data suggests this is true. If tamoxifen causes changes in normal breast tissue on MRI, more study could be done looking at whether breast MRI could tell us anything about whether tamoxifen is working. This study is being done to see if tamoxifen changes normal breast tissue on MRI. It will also look at if other factors like taking anti-depressants or gene type have any effect.
Interventions
OTHERMRI
Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen). During Tamoxifen Treatment: * Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC. * Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique. * Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Females with stage 0-3 breast cancer who have had or are planned to have a breast MRI within 1 year prior to starting tamoxifen * Premenopausal status is defined as intact ovaries and still menstruating * Clinical and MRI follow-up planned at MSKCC or MCKCC regional facility * Willing and able to undergo all study procedures
Exclusion criteria
* Contraindication to breast MRI (such as non-compatible cardiac pacemakers or intracranial vascular clips, allergy to Gadolinium) * Bilateral breast cancer or treatment such as: * History of or planned bilateral breast irradiation * History of or planned bilateral mastectomy * Bilateral breast cancer * History of unilateral mastectomy or radiation treatment with contralateral breast cancer * Taking chemo- or hormonal therapy at the time of the baseline breast MRI * Estrogen and progesterone receptor negative breast cancer * GFR less than GFR \< 30 mL/min/1.73m2 * Postmenopausal women * Pregnant and/or nursing women * Less than 21 years of age
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare the level of BPE on breast MRI | 3 years | on breast MRI in premenopausal patients with breast cancer before and during 9-12 months on tamoxifen to determine whether tamoxifen results in a significant decrease in BPE and/or amount of fibroglandular tissue |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To compare the amount of fibroglandular tissue on breast MRI | 3 years | on breast MRI in premenopausal patients with breast cancer before and during 9-12 months on tamoxifen to determine whether tamoxifen results in a significant decrease in BPE and/or amount of fibroglandular tissue |
Outcome results
None listed